Zobrazeno 1 - 10
of 1 441
pro vyhledávání: '"John C Byrd"'
Autor:
Federico Mosna, Erika Borlenghi, Mark Litzow, John C. Byrd, Cristina Papayannidis, Cristina Tecchio, Felicetto Ferrara, Guido Marcucci, Roberto Cairoli, Elizabeth A. Morgan, Carmela Gurrieri, Cecilia C.S. Yeung, H. Joachim Deeg, Debora Capelli, Anna Candoni, Jason R. Gotlib, Monia Lunghi, Sheeja Pullarkat, Francesco Lanza, Sara Galimberti, Fabio Forghieri, Adriano Venditti, Moreno Festuccia, Ernesta Audisio, Denise Marvalle, Gian Matteo Rigolin, Giovanni Roti, Eros DiBona, Giuseppe Visani, Francesco Albano, Ann-Kathrin Eisfeld, Peter Valent, Gerwin Huls, Gautam Borthakur, Mauro Krampera, Giovanni Martinelli, Nicolaus Kröger, Alessandra Sperotto, Michele Gottardi
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Acute Myeloid Leukemia is mainly a disease of the elderly: however, the knowledge on the outcomes of treatment in core binding factor AML (CBFAML) in older population, is limited. We retrospectively collected data on 229 patients with CBF- AML follow
Externí odkaz:
https://doaj.org/article/f2c7a10b80a14607b116ee33cafabed3
Autor:
Bonnie K Harrington, Heather L Gardner, Raquel Izumi, Ahmed Hamdy, Wayne Rothbaum, Kevin R Coombes, Todd Covey, Allard Kaptein, Michael Gulrajani, Bart Van Lith, Cecile Krejsa, Christopher C Coss, Duncan S Russell, Xiaoli Zhang, Bridget K Urie, Cheryl A London, John C Byrd, Amy J Johnson, William C Kisseberth
Publikováno v:
PLoS ONE, Vol 11, Iss 7, p e0159607 (2016)
Acalabrutinib (ACP-196) is a second-generation inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK) with increased target selectivity and potency compared to ibrutinib. In this study, we evaluated acalabrutinib in spontaneously occurring cani
Externí odkaz:
https://doaj.org/article/885fb92964b3445a99b5a10f0adb8206
Autor:
Kellie J. Archer, Han Fu, Krzysztof Mrózek, Deedra Nicolet, Alice S. Mims, Geoffrey L. Uy, Wendy Stock, John C. Byrd, Wolfgang Hiddemann, Jan Braess, Karsten Spiekermann, Klaus H. Metzeler, Tobias Herold, Ann-Kathrin Eisfeld
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-5 (2024)
Abstract Patients with cytogenetically normal acute myeloid leukemia (CN-AML) may harbor prognostically relevant gene mutations and thus be categorized into one of the three 2022 European LeukemiaNet (ELN) genetic-risk groups. Nevertheless, there rem
Externí odkaz:
https://doaj.org/article/8f315fed381640c280c37db73db5c758
Publikováno v:
Frontiers in Physiology, Vol 6 (2015)
Tetraspanins belong to a family of transmembrane proteins which play a major role in the organization of the plasma membrane. While all immune cells express tetraspanins, most of these are present in a variety of other cell types. There are a select
Externí odkaz:
https://doaj.org/article/f821bd2d377b4b5696e20643135fb26c
Autor:
Janani Ravikrishnan, Daisy Y. Diaz-Rohena, Elizabeth Muhowski, Xiaokui Mo, Tzung-Huei Lai, Shrilekha Misra, Charmelle D. Williams, John Sanchez, Andrew Mitchell, Suresh Satpati, Elizabeth Perry, Tierney Kaufman, Chaomei Liu, Arletta Lozanski, Gerard Lozanski, KerryA Rogers, Adam S. Kittai, Seema A. Bhat, Mary C. Collins, Matthew S. Davids, Nitin Jain, William G. Wierda, Rosa Lapalombella, John C. Byrd, Fenlai Tan, Yi Chen, Yu Chen, Yue Shen, Stephen P. Anthony, Jennifer A. Woyach, Deepa Sampath
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Patients with chronic lymphocytic leukemia (CLL) respond well to initial treatment with the Bcell lymphoma 2 (BCL2) inhibitor venetoclax. Upon relapse, they often retain sensitivity to BCL2 targeting, but durability of response remains a concern. We
Externí odkaz:
https://doaj.org/article/84739096159249b4b8f8ad48426936e4
Autor:
Giovanna Merchand-Reyes, Mikayla F. Bull, Ramasamy Santhanam, Maria L. Valencia-Pena, Rakesh A. Murugesan, Aadesh Chordia, Xiaokui-Molly Mo, Frank H. Robledo-Avila, Juan De Dios Ruiz-Rosado, William Edgar Carson, John C. Byrd, Jennifer A. Woyach, Susheela Tridandapani, Jonathan P. Butchar
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionTherapeutic antibodies have become a major strategy to treat oncologic diseases. For chronic lymphocytic leukemia, antibodies against CD20 are used to target and elicit cytotoxic responses against malignant B cells. However, efficacy is o
Externí odkaz:
https://doaj.org/article/2840c3664e3b44e69f5cbcfe156bc02d
Autor:
Su-Lin Lee, Chih-Chien Chou, Hsiao-Ching Chuang, En-Chi Hsu, Po-Chen Chiu, Samuel K Kulp, John C Byrd, Ching-Shih Chen
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e67149 (2013)
Although the rictor-mTOR complex (mTORC2) has been shown to act as phosphoinositide-dependent kinase (PDK)2 in many cell types, other kinases have also been implicated in mediating Ser473-Akt phosphorylation. Here, we demonstrated the cell line speci
Externí odkaz:
https://doaj.org/article/b2c8fdea46454f19ba16c77a553e7492
Autor:
Erin Hertlein, Kyle A Beckwith, Gerard Lozanski, Timothy L Chen, William H Towns, Amy J Johnson, Amy Lehman, Amy S Ruppert, Brad Bolon, Leslie Andritsos, Arletta Lozanski, Laura Rassenti, Weiqiang Zhao, Tiina M Jarvinen, Leigha Senter, Carlo M Croce, David E Symer, Albert de la Chapelle, Nyla A Heerema, John C Byrd
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e76607 (2013)
Studies of chronic lymphocytic leukemia (CLL) have yielded substantial progress, however a lack of immortalized cell lines representative of the primary disease has hampered a full understanding of disease pathogenesis and development of new treatmen
Externí odkaz:
https://doaj.org/article/6701b5761778490aa7e468949244dd8d
Autor:
Quan-Xiang Wei, Rainer Claus, Thomas Hielscher, Daniel Mertens, Aparna Raval, Christopher C Oakes, Stephan M Tanner, Albert de la Chapelle, John C Byrd, Stephan Stilgenbauer, Christoph Plass
Publikováno v:
PLoS ONE, Vol 8, Iss 1, p e55261 (2013)
We previously reported a rare germline variant (c.1-6531) that resulted in allele-specific expression (ASE) of death-associated protein kinase 1 (DAPK1) and predisposition to chronic lymphocytic leukemia (CLL). We investigated a cohort of CLL patient
Externí odkaz:
https://doaj.org/article/3add295070c94571b56a914a1e10250b
Autor:
Wenjun Ni, Jia Ji, Zunyan Dai, Audrey Papp, Amy J Johnson, Sunjoo Ahn, Katherine L Farley, Thomas S Lin, James T Dalton, Xiaobai Li, David Jarjoura, John C Byrd, Wolfgang Sadee, Michael R Grever, Mitch A Phelps
Publikováno v:
PLoS ONE, Vol 5, Iss 11, p e13792 (2010)
Flavopiridol is a cyclin-dependent kinase inhibitor in phase II clinical development for treatment of various forms of cancer. When administered with a pharmacokinetically (PK)-directed dosing schedule, flavopiridol exhibited striking activity in pat
Externí odkaz:
https://doaj.org/article/d855ac1e3ffb492e8c542945d869e74a